| Source: |
| Type: |
| The effectiveness of chemotherapy by increasing cancer cell sensitivity to the drugs used to treat them, which is known as “chemo-sensitization”. Possible Chemo-Sensitizers: -Curcumin -Resveratrol -EGCG -Quercetin -Genistein -Berberine -Piperine: alkaloid from black pepper -Ginsenosides: active components of ginseng -Silymarin -Allicin -Lycopene -Ellagic acid -Caffeic acid phenethyl ester -flavopiridol -oleandrin -Ursolic acid -butein -Betulinic acid |
| 529- | MF, | Low-frequency magnetic field therapy for glioblastoma: Current advances, mechanisms, challenges and future perspectives |
| - | Review, | GBM, | NA |
| 497- | MF, | In Vitro and in Vivo Study of the Effect of Osteogenic Pulsed Electromagnetic Fields on Breast and Lung Cancer Cells |
| - | vitro+vivo, | BC, | MCF7 | - | vitro+vivo, | Lung, | A549 |
| 501- | MF, | Low Intensity and Frequency Pulsed Electromagnetic Fields Selectively Impair Breast Cancer Cell Viability |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | MCF10 |
| 506- | MF, | doxoR, | Pulsed Electromagnetic Field Stimulation Promotes Anti-cell Proliferative Activity in Doxorubicin-treated Mouse Osteosarcoma Cells |
| - | in-vitro, | OS, | LM8 |
| 512- | MF, | Pulsed Electromagnetic Fields (PEMFs) Trigger Cell Death and Senescence in Cancer Cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | FF95 |
| 4353- | MF, | Chemo, | Pulsed Electromagnetic Field Enhances Doxorubicin-induced Reduction in the Viability of MCF-7 Breast Cancer Cells |
| - | in-vitro, | BC, | MCF7 |
| 4354- | MF, | doxoR, | Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach |
| - | in-vivo, | BC, | MDA-MB-231 | - | in-vivo, | BC, | MCF7 |
| - | in-vitro, | BC, | 4T1 | - | in-vitro, | BC, | MCF7 |
| 2259- | MFrot, | MF, | Method and apparatus for oncomagnetic treatment |
| - | in-vitro, | GBM, | NA |
| 9083- | MGF, | Anti-neoplastic effect of mangiferin on human ovarian adenocarcinoma OVCAR8 cells via the regulation of YAP |
| - | vitro+vivo, | Ovarian, | OVCAR8 |
| 1890- | MGO, | The Dual-Role of Methylglyoxal in Tumor Progression – Novel Therapeutic Approaches |
| - | Review, | Var, | NA |
| 1777- | MLT, | Melatonin as an antioxidant: under promises but over delivers |
| - | Review, | Var, | NA |
| 1779- | MLT, | Therapeutic Potential of Melatonin Counteracting Chemotherapy-Induced Toxicity in Breast Cancer Patients: A Systematic Review |
| - | Review, | BC, | NA |
| 1780- | MLT, | Utilizing Melatonin to Alleviate Side Effects of Chemotherapy: A Potentially Good Partner for Treating Cancer with Ageing |
| - | Review, | Var, | NA |
| 1782- | MLT, | Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities |
| - | Review, | Var, | NA |
| 1786- | MLT, | What is known about melatonin, chemotherapy and altered gene expression in breast cancer (Review) |
| - | Review, | BC, | NA |
| 8669- | MLT, | Melatonin in lung cancer: integrating molecular mechanisms, tumor microenvironment regulation, apoptotic signaling, and therapeutic opportunities |
| - | Review, | Lung, | NA |
| 8659- | MLT, | Cisplatin, | Melatonin Sensitizes OVCAR-3 Cells to Cisplatin through Suppression of PI3K/Akt Pathway |
| - | in-vitro, | Ovarian, | OVCAR-3 |
| 8672- | MLT, | Glioblastoma and Melatonin’s Effects: A Narrative Review |
| - | Review, | GBM, | NA |
| 8693- | MLT, | Mitochondrial cytochrome P450 (CYP) 1B1 is responsible for melatonin-induced apoptosis in neural cancer cells |
| - | in-vitro, | GBM, | U118MG | - | in-vitro, | neuroblastoma, | SH-SY5Y |
| 8687- | MLT, | Melatonin induces cell cycle arrest and suppresses tumor invasion in urinary bladder urothelial carcinoma |
| - | in-vitro, | CRC, | T24/HTB-9 | - | in-vitro, | Bladder, | UMUC3 |
| 8673- | MLT, | Therapeutic Potential of Melatonin in Gastrointestinal Cancers: Molecular Mechanisms, Preclinical Evidence and Clinical Implications |
| - | Review, | GC, | NA |
| 8675- | MLT, | Melatonin combined with antineoplastic drugs or natural products for cancer treatment: An update |
| - | Review, | Var, | NA |
| 3842- | MO, | Bioactive Components in Moringa Oleifera Leaves Protect against Chronic Disease |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 8619- | MO, | doxoR, | Melissa officinalis Protects against Doxorubicin-Induced Cardiotoxicity in Rats and Potentiates Its Anticancer Activity on MCF-7 Cells |
| - | vitro+vivo, | BC, | MCF7 |
| 8895- | MOR, | Cisplatin, | Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin |
| - | in-vitro, | Ovarian, | TOV-21G | - | in-vitro, | Ovarian, | SKOV3 |
| 8897- | MOR, | Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis |
| - | vitro+vivo, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 8874- | MOR, | The anticarcinogenic and anticancer effects of the dietary flavonoid, morin: Current status, challenges, and future perspectives |
| - | Review, | Var, | NA |
| 8868- | MOR, | PacT, | Synergistic effect of morin and paclitaxel impedes cell proliferation through PI3K/AKT/STAT3 signaling axis inhibition in gastric cancer |
| - | in-vitro, | GC, | HGC27 |
| 8867- | MOR, | doxoR, | Morin Sensitizes MDA-MB-231 Triple-Negative Breast Cancer Cells to Doxorubicin Cytotoxicity by Suppressing FOXM1 and Attenuating EGFR/STAT3 Signaling Pathways |
| - | in-vitro, | BC, | MDA-MB-231 |
| 8892- | MOR, | Cisplatin, | Morin Hydrate Reverses Cisplatin Resistance by Impairing PARP1/HMGB1-Dependent Autophagy in Hepatocellular Carcinoma |
| - | vitro+vivo, | HCC, | NA |
| 8889- | MOR, | Selected Flavonols in Breast and Gynecological Cancer: A Systematic Review |
| - | Review, | BC, | NA | - | Review, | Ovarian, | NA |
| 8882- | MOR, | Cisplatin, | Morin hydrate protects against cisplatin-induced testicular toxicity by modulating ferroptosis and steroidogenesis genes' expression and upregulating Nrf2/Heme oxygenase-1 |
| - | in-vivo, | Nor, | NA |
| 8879- | MOR, | doxoR, | Synergistic Effects of Morin and Doxorubicin Overcome Chemoresistance in Ovarian Cancer: Preclinical Insights From in vitro and in vivo Models |
| - | vitro+vivo, | Ovarian, | OVCAR-3 | - | NA, | Melanoma, | A2780S |
| 8876- | MOR, | SRF, | Synergic anticancer effects of morin hydrate and sorafenib delivered via polymeric iron oxide nanoparticles for the treatment of triple-negative breast cancer |
| - | in-vitro, | BC, | NA |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | H4 | - | in-vitro, | Lung, | A549 |
| 8859- | MOR, | Morin inhibits STAT3 tyrosine 705 phosphorylation in tumor cells through activation of protein tyrosine phosphatase SHP1 |
| - | in-vitro, | Melanoma, | U266 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | SCC, | SCC4 | - | in-vitro, | BC, | MCF-10AT |
| 8918- | MP, | Cisplatin, | Mucuna pruriens (L.) DC chemo sensitize human breast cancer cells via downregulation of prolactin-mediated JAK2/STAT5A signaling |
| - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-231 |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | T47D |
| 8775- | MSM, | Methylsulfonylmethane Induces p53 Independent Apoptosis in HCT-116 Colon Cancer Cells |
| - | Review, | Colon, | HCT116 |
| 8772- | MSM, | doxoR, | Methylsulfonylmethane sensitizes endometrial cancer cells to doxorubicin |
| - | in-vitro, | EC, | NA |
| 8803- | MT/VAE, | Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis |
| - | in-vitro, | Var, | NA |
| 8935- | MushCha, | Chaga Mushroom Triterpenoids Inhibit Dihydrofolate Reductase and Act Synergistically with Conventional Therapies in Breast Cancer |
| - | in-vitro, | BC, | SkBr3 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-10AT |
| 8955- | mushLions, | Hericium erinaceus enhances doxorubicin-induced apoptosis in human hepatocellular carcinoma cells |
| - | in-vitro, | HCC, | NA |
| 8956- | mushLions, | 5-FU, | Auxiliary antitumor effects of fungal proteins from Hericium erinaceus by target on the gut microbiota |
| - | in-vivo, | Var, | NA |
| 8967- | mushLions, | Recent developments in mushrooms as anti-cancer therapeutics: a review |
| - | Review, | Var, | NA |
| - | vitro+vivo, | CRC, | HCT116 | - | in-vitro, | CRC, | HT-29 |
| 9302- | MushMait, | Black Maitake mushroom (Grifola frondosa) extract exerts anti-cancer effects and enhances the efficacy of chemotherapeutic drugs in 2D and 3D models of triple-negative breast cancer |
| - | in-vitro, | BC, | MDA-MB-231 |
| 1573- | MushReishi, | Ganoderma lucidum (Reishi mushroom) for cancer treatment |
| - | Review, | Var, | NA |
| 5620- | NaHCO3, | Tumor acidity: From hallmark of cancer to target of treatment |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1106 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid